Acadian Asset Management
ZNTL icon

Acadian Asset Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Acadian Asset Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13M Sell
2,681,900
-166,352
-6% -$664K 0.02% 515
2026
Q1 		$6.66M Sell
2,848,252
-1,042
-0% -$2.69K 0.01% 628
2025
Q4 		$3.84M Buy
2,849,294
+4,142
+0.1% +$6.03K 0.01% 725
2025
Q3 		$4.29M Buy
2,845,152
+46,132
+2% +$69.2K 0.01% 686
2025
Q2 		$3.24M Buy
2,799,020
+124,985
+5% +$165K 0.01% 699
2025
Q1 		$4.24M Buy
2,674,035
+1,606,802
+151% +$3.47M 0.01% 549
2024
Q4 		$3.23M Buy
1,067,233
+804,017
+305% +$2.63M 0.01% 642
2024
Q3 		$967K Buy
+263,216
New +$957K ﹤0.01% 921

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
II
Ishara Investments Los Angeles, California $136M AUM

Acadian Asset Management's ZNTL Position: Q2 2026 in Review

Acadian Asset Management reduced its Zentalis Pharmaceuticals (ZNTL) stake by 5.8% in Q2 2026, selling an estimated $664K and leaving 2,681,900 shares worth $13M. The position accounts for 0.02% of the portfolio, ranked #515.

Acadian Asset Management first reported a position in ZNTL in Q3 2024 and has held it in 8 quarters since. 103 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

  • Acadian Asset Management held 2,681,900 shares of Zentalis Pharmaceuticals worth $13M as of Q2 2026.
  • Acadian Asset Management sold 166,352 Zentalis Pharmaceuticals shares in Q2 2026, an estimated $664K.
  • Zentalis Pharmaceuticals made up 0.02% of Acadian Asset Management's portfolio in Q2 2026, its #515 holding.
  • Acadian Asset Management first reported a position in Zentalis Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
  • 103 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.